Cortexin vs Selank for Mood & Stress: Which Is Better?

Cortexin vs Selank for Mood & Stress: Which Is Better?

When it comes to managing mood and stress naturally, two peptide compounds have emerged from decades of clinical use in Russia and Eastern Europe: Selank and Cortexin. Both are neuropeptide-based compounds with published human research supporting anxiolytic and mood-stabilizing effects. But which one is more effective for your specific mood and stress concerns?

This comparison examines the clinical evidence, mechanisms, dosing, safety, and cost of both compounds to help you understand what the research actually shows.

Disclaimer: This article is educational and informational only. It is not medical advice. Selank and Cortexin are not approved by the FDA for medical use in the United States and exist in a regulatory gray area in most Western countries. Consult a qualified healthcare provider before considering any peptide therapy, especially if you take medications or have existing health conditions.

Overview: What Are Selank and Cortexin?

Selank is a synthetic heptapeptide derived from tuftsin, an endogenous immunopeptide. It was developed by Russia's Institute of Molecular Genetics specifically as an anxiolytic and nootropic agent. Selank is administered via intranasal spray or injection and has been studied in multiple clinical trials for anxiety disorders, generalized anxiety disorder (GAD), and stress-related conditions.

Cortexin is a polypeptide complex derived from the cerebral cortex of cattle or swine, containing a mixture of neuropeptides, amino acids, and vitamins. It has been used in clinical practice across Eastern Europe primarily for cognitive impairment, brain injury recovery, and stroke rehabilitation—though mood and stress research has expanded significantly.

Both are peptide-based compounds with mechanisms that involve neurotrophic factors, neurotransmitter modulation, and neuroprotection. However, their specific formulations, routes of administration, and evidence bases differ meaningfully.

Quick Comparison Table

Selank for Mood & Stress

Evidence Base

Selank has the most direct and robust evidence for anxiety and stress reduction of any peptide compound. The research specifically targeting mood and stress includes 3 randomized controlled trials and 3 observational studies, though sample sizes remain modest.

Key Human Studies:

The most well-controlled trial (n=60, RCT) demonstrated that Selank produced pronounced anxiolytic effects in patients with anxiety disorders, with improvements sustained for one week after the final dose. Quality-of-life measures improved significantly, and patients reported sustained benefit beyond the treatment period.

In another RCT (n=62) comparing Selank directly to medazepam (a benzodiazepine) in patients with generalized anxiety disorder and neurasthenia, Selank demonstrated anxiolytic efficacy equal to medazepam—but with an important distinction: Selank provided additional antiasthenic (anti-fatigue) and psychostimulant effects. The mechanism appeared to involve increased leu-enkephalin levels, which correlated with anxiety reduction. Notably, this study showed that Selank's effects were mediated through endogenous opioid peptide preservation rather than benzodiazepine-like GABAergic suppression.

A third trial (n=70, RCT) tested Selank as an add-on to phenazepam (another benzodiazepine). The results showed that Selank reduced benzodiazepine side effects—including attention and memory impairment, sedation, and sexual disturbances—by 39.6-49.3% while maintaining the anxiolytic efficacy of the benzodiazepine. This suggests Selank may be particularly useful as an adjunctive therapy to reduce benzodiazepine burden.

Mechanism for Mood & Stress

Selank's anxiolytic effects are mediated through several interconnected pathways:

1. GABAergic modulation through GABA-A receptor activity, but with a pharmacological profile distinct from benzodiazepines, which may explain the absence of sedation and dependence risk.

2. Serotonin system enhancement via regulation of serotonin metabolism, contributing to mood stability.

3. Endogenous opioid preservation by inhibiting enkephalin-degrading enzymes, allowing endogenous opioid peptides to persist longer and provide natural anxiolysis.

4. BDNF upregulation, which supports neuroplasticity and may contribute to sustained stress resilience.

5. Immunomodulatory effects via IL-6 and interferon regulation, which may address the inflammation-stress-mood axis.

Side Effects with Selank

For mood and stress use specifically, the most relevant side effects are:

• Mild sedation or drowsiness (more common at higher doses or initial use)
• Transient nasal irritation (with intranasal administration)
• Mild headache
• Slight emotional blunting or flattened affect in some users
• Fatigue, particularly early in a cycle

The emotional blunting effect is worth noting: some users report a dulled emotional responsiveness, which is distinct from the anxiolytic benefit and may be undesirable for those seeking emotional clarity alongside anxiety relief.

Cortexin for Mood & Stress

Evidence Base

Cortexin's evidence for mood and stress is broader but less anxiety-specific. The research includes multiple observational studies and several RCTs demonstrating improvements in anxiety, depression, and emotional symptoms, though the designs are predominantly open-label or non-controlled.

Key Human Studies:

In a study of 98 patients using Cortexin (10 mg/day × 10 days) as an adjunct to antidepressants, researchers found significant decreases in MADRS depression scores (a standard clinician-rated depression scale) and improvements in social functioning (SASS scale) compared to antidepressant-only controls (p=0.001). A larger proportion of the Cortexin + antidepressant group reported "significant" or "substantial" improvement compared to antidepressants alone.

In a larger RCT (n=189) of patients with chronic cerebral ischemia treated with Cortexin (10-20 mg × 10 days), dose-dependent improvements in asthenia and sleep disturbance were observed. However, the study noted that antidepressant and anxiolytic effects were "insignificant" after a single course but improved with repeated treatment—suggesting Cortexin may require multiple courses for sustained mood benefits.

A notable observational study (n=979) of post-COVID patients treated with Cortexin (10-20 mg × 10 days) found that the compound reduced irritability, aggression, and mood disturbances alongside improvements in fatigue, cognitive function, and sleep. This suggests Cortexin may be particularly useful for stress-related emotional dysregulation in post-infectious or post-inflammatory states.

Mechanism for Mood & Stress

Cortexin's mood and stress benefits likely derive from:

1. Neurotrophic factor activation (BDNF, NGF), which supports neuroplasticity and mood stability over time.

2. GABAergic and glutamatergic modulation, reducing excitotoxicity and excessive neural firing that characterizes stress states.

3. Antioxidant activity that reduces free radical-induced neuroinflammation, increasingly recognized as a contributor to depression and anxiety.

4. Neuroprotection and antiapoptotic effects via Bcl-2 family protein modulation, protecting vulnerable neurons from stress-induced damage.

5. Metabolic and DNA repair support at the neuronal level, which may restore resilience over time.

Side Effects with Cortexin

For mood and stress use, the relevant adverse effects are:

• Local injection site reactions (mild pain, redness)
• Transient headache following initial doses
• Dizziness or lightheadedness
• Allergic reactions including urticaria or rash (rare)
• Mild agitation or sleep disturbance if administered late in the day

The risk of agitation or sleep disturbance when dosed late is worth noting for mood management, as improper timing could exacerbate anxiety or sleep issues rather than improve them.

Head-to-Head: Evidence for Mood & Stress

Both compounds carry Tier 3 evidence—meaning probable efficacy based on human studies, but with limitations in scale, rigor, and replication.

Direct Anxiety Reduction

Selank wins for directness of evidence. Three RCTs specifically targeted anxiety disorders or GAD, with pronounced anxiolytic effects documented. One trial directly compared Selank to a benzodiazepine (medazepam) with equivalent efficacy. The mechanisms are anxiety-specific: GABAergic modulation and endogenous opioid preservation.

Cortexin's anxiety evidence is less direct. The largest mood-related trial (n=189) measured asthenia and sleep in chronic cerebral ischemia patients, not primary anxiety outcomes. Cortexin appears to reduce irritability and stress-related mood disturbances, but it's less clearly an anxiolytic in the classical sense.

Depression & Quality of Life

Cortexin has stronger depression-specific evidence. The 98-patient trial showed significant MADRS score reductions when added to antidepressants, with objective improvements in social functioning. This is the most robust evidence for mood improvement in either compound.

Selank's depression data is limited. Quality-of-life improvements were noted in anxiety trials, but MADRS or Hamilton depression scores were not directly measured.

Sustained Effects Post-Treatment

Selank demonstrates sustained benefits. Anxiolytic effects persisted for one week after the final dose in the n=60 trial, suggesting durable neurobiological changes rather than temporary symptom suppression.

Cortexin's sustained effects are less clear. The chronic cerebral ischemia trial noted that mood effects improved with repeated courses, implying that benefits may wane without repeated treatment cycles.

Sample Size & Study Quality

Cortexin has larger trials (up to n=979 observational studies, n=189 RCT) compared to Selank (n=30-70 RCTs). However, Cortexin's larger studies are predominantly observational or open-label, while Selank's smaller trials are more rigorous RCTs.

Dosing Comparison

Selank:

• Intranasal: 250-500 mcg twice daily
• Injection: 250-500 mcg once or twice daily
• Typical course: 14-30 days
• Flexibility: Can be self-administered via nasal spray; injection requires medical administration

Cortexin:

• Injection only: 10 mg once daily
• Typical course: 10 days for acute use; repeated courses for sustained benefit
• Less flexibility: Requires injection administration (subcutaneous or intramuscular)
• Repeated courses: Evidence suggests multiple courses (10-20 days apart) yield better mood outcomes than single courses

Practical difference: Selank offers more convenience with nasal administration and flexibility in dosing frequency. Cortexin's single daily injection is simpler daily protocol but requires professional administration and may require repeated courses.

Safety Comparison

Selank Safety Profile

Selank has a favorable safety profile based on Russian clinical trials with no reported serious adverse events at standard doses. No abuse potential or physical dependence has been documented. The side effect profile is mild and generally self-resolving.

Concern: Long-term safety data from large Western clinical trials is limited, and the compound exists in a regulatory gray area outside Russia and Ukraine. The emotional blunting reported by some users warrants caution for those with mood disorders requiring emotional awareness.

Cortexin Safety Profile

Cortexin has a generally favorable safety profile based on decades of clinical use in Russia, with serious adverse events being rare. As an animal-derived polypeptide complex, there is a theoretical risk of allergic or hypersensitivity reactions that Selank (being synthetic) does not carry.

Concern: Safety data meeting Western regulatory standards is limited. Injection site reactions are common but mild.

Regulatory Status

Selank: Unscheduled but unapproved for medical use outside Russia and Ukraine. Available as a research chemical or supplement in some countries; legal status varies.

Cortexin: Prescription-regulated or pharmacy-only in available countries (primarily Eastern Europe and some CIS nations). Slightly more established in regulated markets but similarly unavailable in Western countries.

Cost Comparison

Selank: $30-$80/month

• More affordable for long-term use
• Lower cost enables extended treatment or repeated courses

Cortexin: $40-$120/month

• Higher cost, particularly if repeated courses are required for sustained benefit
• Injection costs may be higher if administered professionally

For budget-conscious patients seeking sustained mood support, Selank is the more economical choice.

Which Should You Choose for Mood & Stress?

Choose Selank If:

• You have primary anxiety (GAD, generalized anxiety, social anxiety)
• You want direct anxiolytic effects with sustained post-treatment benefit
• You prefer intranasal or flexible injection dosing over daily injections
• You want a lower-cost option for long-term use
• You seek an anxiolytic without the sedation or dependence risk of benzodiazepines
• You want to reduce benzodiazepine side effects if already on one

Choose Cortexin If:

• You have depression alongside stress and anxiety (MADRS improvements are most robust)
• You need improvements in fatigue, cognitive fog, or asthenia alongside mood
• You have underlying neurological conditions (post-stroke, post-COVID, cerebral ischemia) contributing to mood disturbances
• You prefer a single daily injection protocol
• You tolerate animal-derived biologics well (no allergies to bovine/porcine products)
• You're willing to commit to repeated courses for sustained benefit

Combination Consideration:

The evidence supports both compounds as adjunctive therapies—Selank alongside benzodiazepines (reducing side effects) and Cortexin alongside antidepressants (enhancing efficacy). If mood and anxiety are both significant issues, Cortexin for depression + Selank for anxiety might be considered, though no studies have directly examined this combination.

The Bottom Line

Both Selank and Cortexin carry Tier 3 evidence for mood and stress—probable efficacy based on human research, but with limited sample sizes and lack of independent replication.

For primary anxiety: Selank has more specific, direct evidence with sustained post-treatment effects. Three RCTs targeting anxiety disorders and demonstrated efficacy equal to benzodiazepines make it the stronger choice if anxiety is your primary concern.

For depression and multi-symptom mood support: Cortexin has stronger evidence for depression (MADRS improvements) and broader mood effects. If you're dealing with depression, fatigue, and mood disturbances together—particularly in the context of neurological conditions or post-COVID syndrome—Cortexin's evidence is more compelling.

For cost and convenience: Selank is more affordable and offers flexible dosing options.

For established medical context: Cortexin is more regulated in available markets, though both remain unapproved in Western countries and exist in a legal gray area.

Neither compound should replace conventional mood or anxiety treatment without medical supervision. Both should be considered only after consultation with a qualified healthcare provider familiar with peptide therapies and your individual health profile.

The evidence for both is modest but genuine—better than placebo, but not